Clinical trial

Circulating Tumor DNA

NCT06923527

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-09-30

PhasePHASE2

Study timeline

Study start (actual)2025-09-30Date precision: day

Registry last updated2026-09-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

ER+ Breast Cancerunresolved

Interventions

ElacestrantDRUG

Sponsors & collaborators

Yale Universitylead sponsor

Johns Hopkins Universitycollaborator

Stemline Therapeutics, Inc.collaborator

Personalis Inc.collaborator

Mapped research locations

HoustonTexas, United States1 BostonMassachusetts, United States1 BaltimoreMaryland, United States1 PittsburghPennsylvania, United States1 Washington D.C.District of Columbia, United States1 New HavenConnecticut, United States1 The BronxNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06923527 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.